<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348854</url>
  </required_header>
  <id_info>
    <org_study_id>FMTO-103-ISAK</org_study_id>
    <nct_id>NCT01348854</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System</brief_title>
  <official_title>A Multi-Center Prospective Study to Evaluate the Safety and Effectiveness of Arcuate Incisions Performed With the IntraLase iFS Femtosecond Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if arcuate incisions performed with the iFS femtosecond laser are safe and
      effective in reducing corneal astigmatism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgeons will perform arcuate incisions in the cornea in arc segment patterns using the iFS
      femtosecond laser to treat subjects with corneal astigmatism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Astigmatism</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of astigmatism as determined by manifest refractive cylinder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Eyes With Loss of â‰¥ 2 Lines of Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Corneal Astigmatism</condition>
  <arm_group>
    <arm_group_label>Natural Astigmatism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post Cataract with Residual Astigmatism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iFS Femtosecond Laser System</intervention_name>
    <description>arcuate incisions placed with the iFS femtosecond laser</description>
    <arm_group_label>Natural Astigmatism</arm_group_label>
    <arm_group_label>Post Cataract with Residual Astigmatism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, of any race, and at least 21 years of age at the time of pre-op exam

          2. Corneal astigmatism, as determined by topographic keratometry, of 0.75 D to 4.00
             diopters (D)

          3. Best Spectacle Corrected Distance Visual Acuity (BSCVA)

               1. Group 1:

                    -  Natural astigmatism, no cataract - BSCVA of 20/25 or better

                    -  Pre cataract or phakic IOL surgery - no BSCVA criteria

               2. Group 2:

                    -  Post IOL surgery- BSCVA of 20/25 or better

          4. Uncorrected Visual Acuity (UCVA) of 20/40 or worse

          5. Demonstration of agreement: Corneal astigmatism (as determined by topographic
             keratometry) must be in agreement with refractive astigmatism (as determined by
             manifest refractions) within &lt;/= 0.75 D in magnitude and 15 degrees axis when cylinder
             &lt;/= 1.5 D or 10 degrees axis when cylinder &gt; 1.5 D.

          6. Preoperative central pachymetry of &gt;/=480 um

          7. Keratometry between 38.0 D (flat) to 48.0 D (steep)

          8. Corneal power (diopters) difference at the 3mm point from topographic center shall be
             &lt;/= 1D at the steepest meridian

          9. Intraocular pressure of 12 to 21 mm Hg with no glaucomatous retinal/optic nerve
             changes

         10. Subjects who have worn a contact lens within the past 30 days must remove the soft
             lens at least 2 weeks prior and a rigid or toric lens at least 3 weeks prior to
             baseline measurements

         11. Willing and capable of returning for follow-up examinations for the duration of the
             study

        Exclusion Criteria:

          1. Angle kappa of greater than 0.5 mm, absolute value

          2. Prior implantation of toric or multifocal intraocular lens

          3. Women who are pregnant, breast-feeding, or intend to become pregnant over the course
             of the study

          4. Concurrent use of topical or systemic medications that may impair corneal wound
             healing

          5. History of any ocular or medical conditions that could affect corneal wound healing

          6. History of active or recurrent ophthalmic disease, including corneal dystrophy or
             other non-refractive abnormality such as exposure keratitis or clinically significant
             dry eye

          7. Abnormal topography, including evidence of keratoconus or pellucid marginal
             degeneration in either eye

          8. Evidence of clinically significant corneal opacity/scar in the operative eye(s) within
             an 8 mm diameter zone of the visual axis

          9. Known sensitivity or inappropriate responsiveness to any of the medications used in
             the post-operative course

         10. Participation in any other conflicting clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, OD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Optics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privat-Universitat, PMU</name>
      <address>
        <city>Salzburg</city>
        <zip>A5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Potsdamer Augenklinik im</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <results_first_submitted>January 31, 2014</results_first_submitted>
  <results_first_submitted_qc>May 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>astigmatism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Natural Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
        </group>
        <group group_id="P2">
          <title>Post Cataract With Residual Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34">53 eyes of 34 participants</participants>
                <participants group_id="P2" count="6">10 eyes of 6 participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31">47 eyes of 31 participants</participants>
                <participants group_id="P2" count="5">9 eyes of 5 participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.</population>
      <group_list>
        <group group_id="B1">
          <title>Natural Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
        </group>
        <group group_id="B2">
          <title>Post Cataract With Residual Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="16.6"/>
                    <measurement group_id="B2" value="55.0" spread="15.9"/>
                    <measurement group_id="B3" value="53.7" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>paticipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Astigmatism</title>
        <description>Reduction of astigmatism as determined by manifest refractive cylinder</description>
        <time_frame>6 months</time_frame>
        <population>Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.</population>
        <group_list>
          <group group_id="O1">
            <title>Natural Astigmatism</title>
            <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
          </group>
          <group group_id="O2">
            <title>Post Cataract With Residual Astigmatism</title>
            <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Astigmatism</title>
          <description>Reduction of astigmatism as determined by manifest refractive cylinder</description>
          <population>Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.</population>
          <units>diopter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.94"/>
                    <measurement group_id="O2" value="-0.88" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Eyes With Loss of â‰¥ 2 Lines of Best Spectacle Corrected Visual Acuity (BSCVA)</title>
        <time_frame>6 months</time_frame>
        <population>Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.</population>
        <group_list>
          <group group_id="O1">
            <title>Natural Astigmatism</title>
            <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
          </group>
          <group group_id="O2">
            <title>Post Cataract With Residual Astigmatism</title>
            <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Eyes With Loss of â‰¥ 2 Lines of Best Spectacle Corrected Visual Acuity (BSCVA)</title>
          <population>Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Natural Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.</description>
        </group>
        <group group_id="E2">
          <title>Post Cataract With Residual Astigmatism</title>
          <description>Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for auto accident</sub_title>
                <description>Subject hospitalized after auto accident unrelated to study device or procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Penetration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Possible Allergy to Preservative in Ocular Medication</sub_title>
                <description>Subject demonstrated possible allergic response to standard postoperative eye drops which was eliminated by changing to a different type of eye drops.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All proposed submissions for publication or presentation of Trial data must be approved by the Sponsor prior to submission. Under no circumstances shall the Investigator(s) publish or disclose data without the Sponsor's written approval.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>BSCVA determination in eyes with progressing cataracts was sometimes unevaluable, although data are shown as reported.
The number of eyes in &quot;Post Cataract Surgery with Astigmatism&quot; Arm was small, limiting data analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carrie Garufis</name_or_title>
      <organization>Abbott Medical Optics</organization>
      <phone>714-247-8200</phone>
      <email>carrie.garufis@amo.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

